Rx Product News

Pharmacy Times, Volume 0, 0

Tetrix Cream

Marketed by:

Coria Laboratories Ltd (Fort Worth, TX)

Indication:

October 24, 2008—CoriaLaboratories Ltd announced that itintroduced Tetrix Cream, the firstprescription protection for the treatmentof hand eczema and handdermatitis, which is estimated to affect as many as25 million Americans. Tetrix Cream is a nonsteroidalcream comprised of aluminum magnesium hydroxidestearate, cetyl dimethicone copolyol, cyclomethicone,dimethicone, hexyl laurate, polyglyceryl-4-isostearate, purified water, and sodium chloride.It also contains phenoxyethanol and propylparabenas preservatives. The cream may be applied 2 to 3times a day or as prescribed.

Dosage Form:

Supplied in a kit including two 2-oz tubes with 2complimentary 2-oz tubes of CeraVe Cream.

For More Information:

www.corialabs.com

www.TetrixCream.com

866-819-9007

Afluria

Marketed by:

CSL Biotherapies (King of Prussia, PA)

Indication:

September 4, 2008—CSLBiotherapies announced that it began shipment ofAfluria (influenza virus vaccine), in the United Statesfor the 2008-2009 influenza season. Afluria is indicatedfor the active immunization of individuals aged 18years and older against influenza disease caused byinfluenza virus subtypes A and type B. CSL plans todeliver more than 6 million doses of Afluria, and themajority of the supply will be in single-dose, thimerosal-free, prefilled syringes. Afluria was originally grantedmarketing approval by the FDA on September 28,2007. CSL Biotherapies also announced an innovativeonline, quick-ship ordering system, enabling healthcare providers and other purchasers to buy Afluria foradults directly from the company. The new purchasingplatform is available at www.mercuryfreefluvaccine.com.

Dosage Form:

0.5-mL, preservative-free, single-dose, prefilledsyringe; 5-mL multidose vial containing 10 doses

For More Information:

www.Afluria.com

888-435-8633

Astepro

Marketed by:

Meda Pharmaceuticals Inc (Somerset, NJ)

Indication:

October 17, 2008—MedaPharmaceuticals Inc, theUS subsidiary of Meda AB,announced that the FDAapproved Astepro (azelastine hydrochloride)—thenew formulation of Astelin. Astepro Nasal Spray is animprovement over the marketed Astelin Nasal Sprayand is better tolerated by patients using the new spray.The active substance in these products is azelastine—the leading nasal antihistamine in the treatment ofrhinitis in the United States. Astepro is now approvedfor the treatment of seasonal allergic rhinitis.

Dosage Form:

137 mcg per spray

For More Information:

www.medpointepharma.com

Forteo

Marketed by:

Eli Lilly and Co (Indianapolis, IN)

Indication:

October 16, 2008—Eli Lilly and Co announced thatits new, simpler-to-use Forteo (teriparatide [rDNA origin]injection) Delivery Device is available for patientuse in the United States. The new delivery device wasdesigned specifically for Forteo patients to help themmore easily administer their treatment on a day-to-daybasis. Originally approved by the FDA in June, the newdelivery device is now being shipped to pharmaciesand will be available for patients when they fill theirprescriptions. Forteo is indicated for the treatment ofosteoporosis in postmenopausal women who are athigh risk for fracture and to increase bone mass in menwith primary or hypogonadal osteoporosis who are athigh risk for fracture.

Dosage Form:

20 mcg once daily

For More Information:

www.FORTEO.com

Rapaflo

Marketed by:

Watson Pharmaceuticals Inc (Corona, CA)

Indication:

October 8, 2008—Watson Pharmaceuticals Incannounced that the FDA approved Rapaflo (silodosin),the company's new alpha-blocker for the treatmentof signs and symptoms of benign prostatic hyperplasia(BPH). BPH is the number-1 reason patients visiturologists and is characterized by urination problems,including decreased urine flow, more frequent urination,and nocturia. Rapaflo is an effective, selectivealpha-1 adrenergic receptor antagonist.

Dosage Form:

Capsules: 4 and 8 mg

For More Information:

www.watson.com

Reyataz

Marketed by:

Bristol-Myers Squibb Co (Princeton, NJ)

Indication:

October 1, 2008—Bristol-MyersSquibb Co announced that theFDA approved the use of Reyataz(atazanavir sulfate) 300 mgonce-daily boosted with ritonavir100 mg as part of combinationtherapy in previously untreated (treatment-na?ve) HIV-1?infected patients. Reyataz is a protease inhibitorused in combination with other antiretroviral agentsto treat individuals who are infected with HIV. Reyatazboosted with ritonavir taken once daily with foodis recognized by the US Department of Health andHuman Services as a preferred component of combinationHIV therapy for treatment-na?ve patients.

Dosage Form:

Capsules: 100, 150, 200, and 300 mg

For More Information:

www.reyataz.com

www.BMS.com

Find it Online

For more Rx Product News, visit www.PharmacyTimes.com/Rxproducts